Core Viewpoint - Yuaneng Bio has officially launched its Series B financing and is actively preparing for its listing on the Sci-Tech Innovation Board, focusing on the automation of low-temperature storage technology in the biopharmaceutical sector [1][6]. Group 1: Company Overview - Yuaneng Bio has been dedicated to the research and development of advanced automated low-temperature storage equipment for nearly eight years, with an investment of approximately 800 million yuan [3][6]. - The company has applied for over 600 domestic and international patents, with more than 500 granted [1][3]. - The company aims to transform low-temperature storage technology from laboratory applications to industrialization, driven by policy, capital, and entrepreneurial efforts [1][6]. Group 2: Product Development - Yuaneng Bio has developed a series of automated deep low-temperature biological sample storage devices, achieving a breakthrough from 0 to 1 in research and development [3][6]. - The company has introduced a "honeycomb" storage structure that physically isolates each sample to avoid cross-contamination [3][6]. - The product matrix includes various series such as BSN, P, AM, IVF, PBM, and BSE, successfully implemented in multiple projects across health and research institutions [3][4]. Group 3: Market Strategy - The company is currently in the small-batch manufacturing phase, focusing on standardizing and modularizing its products to reduce production costs for future mass manufacturing [4][6]. - Yuaneng Bio is expanding its market presence domestically while also enhancing collaboration with global partners to attract overseas customers [4][6]. - The company has received recognition for its Orcella duo 1100S automated deep low-temperature storage system, winning the "Outstanding New Product Award" at an international event [4]. Group 4: Future Outlook - The company plans to accelerate the application of its technology in various sectors, including hospitals, disease control centers, and biopharmaceutical companies [6]. - There is a significant focus on the future potential of cell storage, with aspirations for it to become a common practice for families [6]. - Yuaneng Bio is set to complete a new smart manufacturing base in Shanghai in 2024, with a total area of nearly 10,000 square meters [6].